List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 25 studies with search of: Ribose
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Suspended The Role of Ribose in Patients Diagnosed With Fibromyalgia
Condition: Fibromyalgia
Interventions: Dietary Supplement: D-ribose;   Other: dextrose
2 Completed The Effect of Oral D-Ribose in "Baby Boomers" With Fatigue. A Randomized, Double-Blind Study
Condition: Fatigue
Interventions: Dietary Supplement: D-ribose;   Dietary Supplement: Dextrose
3 Terminated The Effect of Ribose on B-Type Natriuretic Peptide (BNP) Levels in Congestive Heart Failure Patients
Condition: Congestive Heart Failure
Intervention: Drug: CORvalen (D-Ribose)
4 Completed Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity
Condition: 5'-Nucleotidase Syndrome
Interventions: Drug: ribose;   Drug: thymidine;   Drug: uridine
5 Active, not recruiting A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
Conditions: Ovarian Neoplasms;   BRCA1 Protein;   BRCA2 Protein
Intervention: Drug: KU-0059436 (AZD2281)(PARP inhibitor)
6 Recruiting Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
Condition: Glioblastoma
Intervention: Drug: bsi-201 plus temozolomide
7 Not yet recruiting A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
Condition: Advanced Solid Tumors
Interventions: Drug: PF-01367338;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Pemetrexed
8 Completed Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours
Condition: Neoplasm Metastasis
Intervention: Drug: AZD2281
9 Completed A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention
Condition: Acute Myocardial Infarction
Intervention: Drug: INO-1001
10 Recruiting ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: ABT-888;   Drug: temozolomide;   Other: laboratory biomarker analysis;   Other: pharmacological study
11 Completed ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
Conditions: Leukemia;   Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: ABT-888;   Other: pharmacological study;   Procedure: biopsy
12 Recruiting ABT-888 and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cavity Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: ABT-888;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
13 Completed Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
Condition: Malignant Solid Tumors
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor);   Drug: Topotecan
14 Completed A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
Condition: Melanoma Neoplasms
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor);   Drug: dacarbazine
15 Recruiting Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin
Conditions: Malignant Solid Tumours;   Carboplatin;   Paclitaxel
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor);   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Paclitaxel + Carboplatin
16 Completed Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-Positive Advanced Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: KU-0059436 (AZD2281)(PARP inhibitor)
17 Completed Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-Positive Advanced Ovarian Cancer
Condition: Ovarian Neoplasm
Intervention: Drug: KU-0059436 (AZD2281)(PARP inhibitor)
18 Active, not recruiting Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: AZD2281;   Drug: Liposomal Doxorubicin
19 Recruiting Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor);   Drug: Gemcitabine
20 Completed Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours
Condition: Neoplasm Metastasis
Interventions: Drug: AZD2281;   Drug: Bevacizumab

Previous Page Studies Shown (1-20) Next Page (21-25)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services